Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ianalumab device comparability crossover PK study in autoimmune disease
NL-OMON58893Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ianalumab in systemic lupus erythematosus (SLE), Sjögren's syndrome and rheumatoid arthritis (RA) (4 cohorts), sponsored by Novartis. Primary endpoints: AUCtau and Cmax. Started Jun 2024; status: completed.
02
Drugs
ianalumab
03
Conditions
systemic lupus erythematosus (SLE)Sjögren's syndromerheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON58893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58893.